Brainsway (BWAY) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Brainsway (BWAY) is set to release its Q2 2025 earnings on August 5th, with analysts predicting earnings of $0.07 per share and revenue of $12.34 million.
• The company recently reported a net margin of 9.01% and a return on equity of 7.35% in its last earnings results, beating expectations with a reported EPS of $0.04.
• HC Wainwright has reiterated a "buy" rating for Brainsway with a price target of $16.00 per share, indicating positive sentiment from analysts.

Brainsway (NASDAQ:BWAY - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 5th. Analysts expect Brainsway to post earnings of $0.07 per share and revenue of $12.34 million for the quarter. Brainsway has set its FY 2025 guidance at EPS.

Brainsway (NASDAQ:BWAY - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The business had revenue of $11.54 million during the quarter, compared to the consensus estimate of $11.45 million. Brainsway had a net margin of 9.01% and a return on equity of 7.35%. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Brainsway Price Performance

Brainsway stock traded down $0.08 during trading hours on Wednesday, reaching $11.75. The stock had a trading volume of 14,767 shares, compared to its average volume of 47,874. Brainsway has a 52 week low of $5.98 and a 52 week high of $13.65. The company has a market cap of $222.08 million, a price-to-earnings ratio of 58.75 and a beta of 1.40. The business's 50 day moving average price is $11.69 and its 200-day moving average price is $10.39.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Brainsway stock. NewEdge Advisors LLC raised its stake in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 61.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,828 shares of the company's stock after acquiring an additional 7,549 shares during the quarter. NewEdge Advisors LLC owned approximately 0.11% of Brainsway worth $188,000 at the end of the most recent reporting period. 30.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and set a $16.00 price target on shares of Brainsway in a research note on Monday, June 9th.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.